1-(2-呋喃甲基)-5-氧吡咯烷-3-羧酸 | 175136-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(2-呋喃甲基)-5-氧吡咯烷-3-羧酸
• 中文别名: 1-(2-呋喃甲基)-5-氧吡咯-3-羧酸
• 英文名称: 1-(furan-2-ylmethyl)-5-oxopyrrolidine-3-carboxylic acid
• 英文别名: 1-(2-furylmethyl)-5-oxo-3-pyrrolidinecarboxylic acid；1-(2-Furylmethyl)-5-oxopyrrolidine-3-carboxylic acid
• CAS: 175136-93-3
• 化学式: C₁₀H₁₁NO₄
• mdl: MFCD00084926
• 分子量: 209.202
• InChiKey: NFWHHUCJMAPGHE-UHFFFAOYSA-N

物化性质

• 熔点：
  159 °C
• 沸点：
  460.8±45.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  1-(2-呋喃甲基)-5-氧吡咯烷-3-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-Furan-2-ylmethyl-5-oxo-pyrrolidine-3-carbonyl chloride
  参考文献：
  名称：

  CCR5 Antagonists as Anti-HIV-1 Agents. 1. Synthesis and Biological Evaluation of 5-Oxopyrrolidine-3-carboxamide Derivatives

  摘要：

  一种新型的铅化合物N-{3-[4-(4-氟苯甲酰)piperidin-1-基]丙基}-1-甲基-5-氧代-N-苯基吡咯烷-3-羧酰胺（1）通过高通量筛选与[125I]RANTES和CCR5表达的CHO细胞被鉴定为CCR5拮抗剂。化合物1的IC50值为1.9 μM。为了提高化合物1的结合亲和力，合成了一系列5-氧代吡咯烷-3-羧酰胺。向中心苯环引入3,4-二氯取代基（10i，IC50=0.057 μM；11b，IC50=0.050 μM）或用1-苄基取代5-氧代吡咯烷部分的1-甲基基团（12e，IC50=0.038 μM）被发现有效提高了对CCR5的亲和力。化合物10i、11b和12e也分别以0.44、0.19和0.49 μM的IC50值抑制了CCR5使用的HIV-1包膜介导的膜融合。

  DOI：

  10.1248/cpb.52.63
• 作为产物：
  描述：

  衣康酸二甲酯 在 水 、 potassium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 2.0h， 生成 1-(2-呋喃甲基)-5-氧吡咯烷-3-羧酸
  参考文献：
  名称：

  Inhibition of noroviruses by piperazine derivatives

  摘要：

  There is currently an unmet need for the development of small-molecule therapeutics for norovirus infection. The piperazine scaffold, a privileged structure embodied in many pharmacological agents, was used to synthesize an array of structurally-diverse derivatives which were screened for anti-norovius activity in a cell-based replicon system. The studies described herein demonstrate for the first time that functionalized piperazine derivatives possess anti-norovirus activity. Furthermore, these studies have led to the identification of two promising compounds (6a and 9I) that can be used as a launching pad for the optimization of potency, cytotoxicity, and drug-like characteristics. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.122

文献信息

• Inhibitors of cathepsin S
  申请人：IRM LLC

  公开号：US20040198780A1

  公开（公告）日：2004-10-07

  The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.

  本发明提供了用于选择性抑制蛋白酶S的化合物、组合物和方法。在一个优选方面，当至少存在另一种蛋白酶同工酶（例如，蛋白酶K）时，选择性地抑制蛋白酶S。本发明还提供了通过选择性抑制蛋白酶S来治疗受试者疾病状态的方法。
• [EN] CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT<br/>[FR] INHIBITEURS D'AMINES CYCLIQUES BACE-1 RENFERMANT UN SUBSTITUANT HETEROCYCLIQUE
  申请人：SCHERING CORP

  公开号：WO2005014540A1

  公开（公告）日：2005-02-17

  Disclosed are novel compounds of the formula (I)or a pharmaceutically acceptable salt or solvate thereof, wherein R1 is formula (I) X is -0-, -C(R14)2- or -N(R)-; Z is -C(R14)2- or -N(R)-; t is 0, 1, 2 or 3; each R and R2 is independently H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, alkenyl or alkynyl; each R14 is H, alkyl, alkenyl, alkynyl, halo, -CN, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, heterocycloalkylalkyl, -OR35, -N(R24)(R25) or -SR35; R41 is alkyl, cycloalkyl, -S02(alkyl), -C(O)-alkyl, -C(O)-cycloalkyl or -alkyl-NH-C(O)CH3; and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I and methods of treating cognitive or neurodegenerative diseases with compounds of formula (I). Also disclosed are pharmaceutical compositions and methods of treatment comprising compounds of formula I in combination with other agents useful in treating cognitive or neurodegenerative diseases.

  揭示了具有以下结构的新化合物（I）或其药学上可接受的盐或溶剂，其中R1为结构（I），X为-0-，-C(R14)2-或-N(R)-；Z为-C(R14)2-或-N(R)-；t为0、1、2或3；每个R和R2独立地为H、烷基、环烷基、环烷基烷基、芳基、杂环芳基、杂环烷基、芳基烷基、杂环芳基烷基、杂环烷基烷基、烯基或炔基；每个R14为H、烷基、烯基、炔基、卤素、-CN、卤代烷基、环烷基、环烷基烷基、芳基、杂环芳基、芳基烷基、杂环芳基烷基、杂环烷基烷基、-OR35、-N(R24)(R25)或-SR35；R41为烷基、环烷基、-S02(烷基)、-C(O)-烷基、-C(O)-环烷基或-烷基-NH-C(O)CH3；其余变量如规范中所定义。还揭示了包括化合物的药物组合物（I）的制剂以及使用化合物（I）治疗认知或神经退行性疾病的方法。还揭示了包括化合物（I）的药物组合物和治疗方法，其与治疗认知或神经退行性疾病有用的其他药剂结合使用。
• Continuous Flow Synthesis under High-Temperature/High-Pressure Conditions Using a Resistively Heated Flow Reactor
  作者：Ahmed Adeyemi、Joakim Bergman、Jonas Brånalt、Jonas Sävmarker、Mats Larhed

  DOI：10.1021/acs.oprd.7b00063

  日期：2017.7.21

  easy-to-build, and effective resistively heated reactor for continuous flow synthesis at high temperature and pressure is herein presented. The reactor is rapidly heated directly using an electric current and is capable of rapidly delivering temperatures and pressures up to 400 °C and 200 bar, respectively. High-temperature and high-pressure applications of this reactor were safely performed and demonstrated

  本文提出了一种便宜，易于建造且有效的电阻加热反应器，用于在高温和高压下进行连续流合成。使用电流直接对反应器进行快速加热，并且能够分别快速输送高达400°C和200 bar的温度和压力。该反应器的高温和高压应用是安全进行的，并通过选择的转化（例如酯化，酯交换和使用超临界乙醇，甲醇和乙腈将羧酸直接转化为腈反应）进行了证明。反应温度在300到400°C之间，具有出色的转化率和良好的分离产物收率。Diels–Alder反应的实例还可以在高达300°C的温度下以高收率进行。
• Methods and compositions for determining the sequence of nucleic acid molecules
  申请人：QIAGEN Genomics, Inc.

  公开号：US20040115694A1

  公开（公告）日：2004-06-17

  Methods and compounds, including compositions therefrom, are provided for determining the sequence of nucleic acid molecules. The methods permit the determination of multiple nucleic acid sequences simultaneously. The compounds are used as tags to generate tagged nucleic acid fragments which are complementary to a selected target nucleic acid molecule. Each tag is correlative with a particular nucleotide and, in a preferred embodiment, is detectable by mass spectrometry. Following separation of the tagged fragments by sequential length, the tags are cleaved from the tagged fragments. In a preferred embodiment, the tags are detected by mass spectrometry and the sequence of the nucleic acid molecule is determined therefrom. The individual steps of the methods can be used in automated format, e.g., by the incorporation into systems.

  提供了用于确定核酸分子序列的方法和化合物，包括从中制备的组合物。该方法允许同时确定多个核酸序列。这些化合物被用作标记，以生成与所选目标核酸分子互补的带标记的核酸片段。每个标记与特定的核苷酸相关，在优选实施例中，可以通过质谱法检测到。在通过顺序长度分离带标记的片段后，将从带标记的片段中切除标记。在优选实施例中，通过质谱法检测标记，并从中确定核酸分子的序列。该方法的各个步骤可以以自动化格式使用，例如通过纳入系统中。
• Pyrazole compounds and pharmaceutical compositions comprising the compound
  申请人：Ohi Norihito

  公开号：US20050208582A1

  公开（公告）日：2005-09-22

  The present invention provides a novel compound having an excellent JNK inhibitory effect. That is, it provides a compound represented by the following formula, a salt thereof or a hydrate of them. Wherein R 1 designates —(CO h —(NR a ) j —(CR b ═CR c ) k —Ar (wherein R a , R b and R c each independently designate a hydrogen atom, a halogen atom, hydroxyl group, an optionally substituted C 1-6 alkyl group or the like; Cy designates a 5- or 6-membered heteroaryl; and V each independently designate the formula -L-X—Y (wherein L designates a single bond, an optionally substituted C 1-6 alkylene group or the like; X designates a single bond or the formula -A- (wherein A designates NR 2 , O, CO, S, SO or SO 2 ) and so on; and Y designates a hydrogen atom, a halogen atom, nitro group or the like).

  本发明提供了一种具有优异的JNK抑制作用的新型化合物。即，提供了下式所示的化合物，其盐或水合物。其中，R1表示—(COh—(NRa)j—(CRb═CRc)k—Ar（其中Ra，Rb和Rc各自独立地表示氢原子，卤素原子，羟基，选自C1-6烷基等的可选取代基团；Cy表示5-或6-成员杂环芳基；V各自独立地表示公式-L-X—Y（其中L表示单键，选自C1-6烷基等的可选取代基团；X表示单键或公式-A-（其中A表示NR2，O，CO，S，SO或SO2）等；Y表示氢原子，卤素原子，硝基或类似物）。